$BLUE
bluebird bio, Inc.

2019 Q3 Form 10-Q Financial Statement

#000156459019039179 Filed on October 31, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q3 2018 Q2
Revenue $8.910M $11.53M $7.851M
YoY Change -22.71% 49.5% -53.03%
Cost Of Revenue $862.0K $29.00K $21.00K
YoY Change 2872.41% -97.36% -95.0%
Gross Profit $8.048M $11.50M $7.830M
YoY Change -30.01% 73.94% -51.95%
Gross Profit Margin 90.33% 99.75% 99.73%
Selling, General & Admin $66.25M $44.50M $41.20M
YoY Change 48.88% 93.48% 94.34%
% of Gross Profit 823.19% 386.99% 526.18%
Research & Development $151.4M $116.7M $115.0M
YoY Change 29.7% 89.69% 78.84%
% of Gross Profit 1881.36% 1015.25% 1468.89%
Depreciation & Amortization $4.550M $4.410M $4.180M
YoY Change 3.17% 21.82% 21.51%
% of Gross Profit 56.54% 38.35% 53.38%
Operating Expenses $217.7M $161.3M $156.5M
YoY Change 34.9% 89.0% 85.08%
Operating Profit -$210.4M -$149.8M -$148.6M
YoY Change 40.45% 92.92% 119.12%
Interest Expense $8.417M $4.591M $2.436M
YoY Change 83.34% -497.49% -208.65%
% of Operating Profit
Other Income/Expense, Net -$4.298M -$252.0K $182.0K
YoY Change 1605.56% -3250.0% -121.82%
Pretax Income -$206.3M -$145.5M -$146.0M
YoY Change 41.8% 84.61% 105.92%
Income Tax -$264.0K
% Of Pretax Income
Net Earnings -$206.0M -$145.5M -$146.0M
YoY Change 41.62% 84.61% 105.92%
Net Earnings / Revenue -2312.38% -1261.97% -1859.58%
Basic Earnings Per Share
Diluted Earnings Per Share -$3.725M -$2.730M -$2.908M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.406B $1.675B $1.077B
YoY Change -16.08% 129.87% -1.68%
Cash & Equivalents $300.4M $952.1M $333.9M
Short-Term Investments $1.105B $723.1M $743.0M
Other Short-Term Assets $40.00M $30.00M $28.80M
YoY Change 33.33% 10.29% 53.19%
Inventory
Prepaid Expenses $26.93M $24.13M
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $1.220B $1.725B $1.106B
YoY Change -29.29% 127.41% -1.15%
LONG-TERM ASSETS
Property, Plant & Equipment $144.1M $232.9M $219.2M
YoY Change -38.12% 27.67% 21.49%
Goodwill $13.13M $13.13M
YoY Change 0.0%
Intangibles $15.40M $14.11M
YoY Change 9.13%
Long-Term Investments $225.9M $323.8M $380.3M
YoY Change -30.23% -21.77% 274.31%
Other Assets $82.07M $42.57M $28.10M
YoY Change 92.79% 114.99% 14.69%
Total Long-Term Assets $672.2M $626.4M $655.8M
YoY Change 7.3% -3.19% 93.73%
TOTAL ASSETS
Total Short-Term Assets $1.220B $1.725B $1.106B
Total Long-Term Assets $672.2M $626.4M $655.8M
Total Assets $1.892B $2.352B $1.762B
YoY Change -19.54% 67.29% 20.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $41.87M $12.89M $17.90M
YoY Change 224.83% 4.8% 24.1%
Accrued Expenses $113.9M $86.40M $68.70M
YoY Change 31.83% 109.2% 63.57%
Deferred Revenue $8.474M $22.58M $27.32M
YoY Change -62.46%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $1.300M $1.200M
YoY Change -100.0% 62.5%
Total Short-Term Liabilities $196.0M $131.6M $116.3M
YoY Change 48.96% 71.35% 49.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $153.7M $154.1M
YoY Change -100.0% -0.32% 0.06%
Other Long-Term Liabilities $3.726M $2.634M $33.60M
YoY Change 41.46% -92.11% 37233.33%
Total Long-Term Liabilities $3.726M $2.634M $187.7M
YoY Change 41.46% -98.6% 208455.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $196.0M $131.6M $116.3M
Total Long-Term Liabilities $3.726M $2.634M $187.7M
Total Liabilities $420.5M $351.0M $304.0M
YoY Change 19.8% 32.75% 18.24%
SHAREHOLDERS EQUITY
Retained Earnings -$2.059B -$1.350B
YoY Change 52.51%
Common Stock $553.0K $547.0K
YoY Change 1.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.472B $2.001B $1.458B
YoY Change
Total Liabilities & Shareholders Equity $1.892B $2.352B $1.762B
YoY Change -19.54% 67.29% 20.89%

Cashflow Statement

Concept 2019 Q3 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$206.0M -$145.5M -$146.0M
YoY Change 41.62% 84.61% 105.92%
Depreciation, Depletion And Amortization $4.550M $4.410M $4.180M
YoY Change 3.17% 21.82% 21.51%
Cash From Operating Activities -$113.4M -$74.48M -$100.4M
YoY Change 52.23% 32.22% 87.52%
INVESTING ACTIVITIES
Capital Expenditures -$24.93M -$22.15M -$13.24M
YoY Change 12.55% 467.95% -1.85%
Acquisitions
YoY Change
Other Investing Activities $154.0M $56.02M -$14.25M
YoY Change 174.87% -114.19% -119.66%
Cash From Investing Activities $129.0M $33.87M -$27.48M
YoY Change 280.99% -108.49% -146.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.180M 658.8M 5.300M
YoY Change -99.37% 10664.54% -98.86%
NET CHANGE
Cash From Operating Activities -113.4M -74.48M -100.4M
Cash From Investing Activities 129.0M 33.87M -27.48M
Cash From Financing Activities 4.180M 658.8M 5.300M
Net Change In Cash 19.84M 618.2M -122.6M
YoY Change -96.79% -237.68% -126.06%
FREE CASH FLOW
Cash From Operating Activities -$113.4M -$74.48M -$100.4M
Capital Expenditures -$24.93M -$22.15M -$13.24M
Free Cash Flow -$88.45M -$52.33M -$87.16M
YoY Change 69.02% -0.19% 117.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
300426000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
402579000
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
879529000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
982725000
CY2019Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
26932000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
19762000
CY2019Q3 blue Receivables And Other Current Assets
ReceivablesAndOtherCurrentAssets
13145000
CY2018Q4 blue Receivables And Other Current Assets
ReceivablesAndOtherCurrentAssets
13931000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
1220032000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
1418997000
CY2019Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
225932000
CY2018Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
506123000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
144097000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
246622000
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15397000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13169000
CY2019Q3 us-gaap Goodwill
Goodwill
13128000
CY2018Q4 us-gaap Goodwill
Goodwill
13128000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
191563000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82069000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
44805000
CY2019Q3 us-gaap Assets
Assets
1892218000
CY2018Q4 us-gaap Assets
Assets
2242844000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
41874000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17831000
CY2019Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
112479000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
99393000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19931000
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8474000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18602000
CY2019Q3 blue Collaboration Research Advancement Current
CollaborationResearchAdvancementCurrent
13273000
CY2018Q4 blue Collaboration Research Advancement Current
CollaborationResearchAdvancementCurrent
10605000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
196031000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
146431000
CY2019Q3 blue Collaboration Research Advancement Non Current
CollaborationResearchAdvancementNonCurrent
26273000
CY2018Q4 blue Collaboration Research Advancement Non Current
CollaborationResearchAdvancementNonCurrent
33349000
CY2019Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6542000
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5230000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55320000
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55320000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54738000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54738000
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
553000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
547000
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3532513000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3386958000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2851000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3627000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2058505000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1498808000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
1471710000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1885070000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1892218000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2242844000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8910000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11528000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34677000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35336000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
151412000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
116744000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
420592000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
328867000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
66250000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44527000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
195160000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
120621000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
862000
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
29000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1905000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
67000
CY2019Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
802000
CY2018Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
47000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1312000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
843000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
219326000
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
161347000
us-gaap Costs And Expenses
CostsAndExpenses
618969000
us-gaap Costs And Expenses
CostsAndExpenses
450398000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-210416000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-149819000
us-gaap Operating Income Loss
OperatingIncomeLoss
-584292000
us-gaap Operating Income Loss
OperatingIncomeLoss
-415062000
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8417000
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4591000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
27906000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8415000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4298000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-252000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10623000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
45000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-206297000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-145480000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-567009000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-406602000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-264000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-748000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-206033000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-145480000
us-gaap Net Income Loss
NetIncomeLoss
-566261000
us-gaap Net Income Loss
NetIncomeLoss
-406602000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.73
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
blue:LicenseAndRoyaltyMember
CY2018Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
blue:LicenseAndRoyaltyMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
blue:LicenseAndRoyaltyMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
blue:LicenseAndRoyaltyMember
CY2019Q3 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
blue:ReceivablesAndOtherCurrentAssets
CY2018Q3 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
blue:ReceivablesAndOtherCurrentAssets
CY2019Q3 us-gaap Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2018Q3 us-gaap Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.73
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.27
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
11910000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
16338000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
176026000
CY2018Q4 blue Financing Lease Obligation Noncurrent
FinancingLeaseObligationNoncurrent
153319000
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3726000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3107000
CY2019Q3 us-gaap Liabilities
Liabilities
420508000
CY2018Q4 us-gaap Liabilities
Liabilities
357774000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53277000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55139000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51130000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.95
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55292000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
2000790000
us-gaap Profit Loss
ProfitLoss
-566261000
CY2019Q3 blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
0.0
CY2018Q3 blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
0.0
blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
1300000
blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
0.0
CY2019Q3 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities And Pension And Other Postretirement Benefit Plans Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesAndPensionAndOtherPostretirementBenefitPlansArisingDuringPeriodNetOfTax
-2032000
CY2018Q3 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities And Pension And Other Postretirement Benefit Plans Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesAndPensionAndOtherPostretirementBenefitPlansArisingDuringPeriodNetOfTax
-66000
blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities And Pension And Other Postretirement Benefit Plans Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesAndPensionAndOtherPostretirementBenefitPlansArisingDuringPeriodNetOfTax
776000
blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities And Pension And Other Postretirement Benefit Plans Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesAndPensionAndOtherPostretirementBenefitPlansArisingDuringPeriodNetOfTax
-1255000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2032000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-66000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
776000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1255000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-208065000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-145546000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-565485000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-407857000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1885070000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9504000
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1231000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32341000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1835000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-164446000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
1772099000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3973000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
55111000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
973000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-195782000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3321000
CY2019Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1535000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
38546000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2032000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-206033000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
1471710000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
1623432000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2563000
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48701000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19730000
CY2018Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
687000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22995000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-844000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-115126000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
1570201000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5617000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28056000
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-345000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-145996000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
1457534000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
32025000
CY2018Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
600667000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2940000
CY2018Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
917000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29797000
CY2018Q3 blue Stock Issued During Period Value In Connection With Collaborative Arrangement
StockIssuedDuringPeriodValueInConnectionWithCollaborativeArrangement
54484000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-66000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-145480000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
735771000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-61672000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
952137000
CY2019Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
us-gaap Profit Loss
ProfitLoss
-406602000
blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
1312000
blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
843000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
12378000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
12613000
us-gaap Share Based Compensation
ShareBasedCompensation
125998000
us-gaap Share Based Compensation
ShareBasedCompensation
80849000
us-gaap Available For Sale Equity Securities Gross Unrealized Loss
AvailableForSaleEquitySecuritiesGrossUnrealizedLoss
9778000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
9362000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3106000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10672000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
19014000
blue Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-16687000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
23280000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-493000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
15260000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
31466000
blue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4843000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-14556000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31981000
blue Increase Decrease In Collaboration Research Advancement
IncreaseDecreaseInCollaborationResearchAdvancement
4407000
blue Increase Decrease In Collaboration Research Advancement
IncreaseDecreaseInCollaborationResearchAdvancement
-45518000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-405408000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-283695000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
58638000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42844000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
646937000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
827163000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
1034353000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
631680000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
4224000
blue Payments To Acquire Other Investments And Investment Receivable
PaymentsToAcquireOtherInvestmentsAndInvestmentReceivable
20017000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
324554000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-258344000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
649367000
blue Proceeds From Reimbursement Of Assets Under Financing Lease Obligation
ProceedsFromReimbursementOfAssetsUnderFinancingLeaseObligation
3098000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
728000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19182000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29550000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19182000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
193732000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417099000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
772268000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
355427000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
966000000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
300426000
CY2018Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2019Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
54901000
CY2018Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
13763000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
355427000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
966000000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6611000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2770000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
23939000
us-gaap Nature Of Operations
NatureOfOperations
<p id="Note_to_Condensed" style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Cambridge, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s programs in severe genetic diseases include ZYNTEGLO<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (autologous CD34+ cells encoding β<sup style="font-size:85%;line-height:120%;vertical-align:top">A-T87Q</sup>-globin gene) gene therapy as a treatment for transfusion-dependent β-thalassemia, or TDT; its LentiGlobin<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> product candidate as a treatment for sickle cell disease, or SCD; and its Lenti-D<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> product candidate as a treatment for cerebral adrenoleukodystrophy, or CALD. The Company’s programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Idecabtagene vicleucel, or ide-cel, and bb21217, which are product candidates in oncology under the Company’s collaboration arrangement with Celgene Corporation (“Celgene”), are CAR T cell product candidates for the treatment of multiple myeloma. Please <span style="color:#000000;">refer</span> to Note 9, “<span style="font-style:italic;">Collaborative arrangements</span>” for further discussion of the Company’s collaboration with Celgene<span style="color:#000000;">.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company received conditional marketing authorization from the European Commission for ZYNTEGLO (formerly referred to as LentiGlobin for TDT) for the treatment of patients 12 years and older with TDT who do not have a β<sup style="font-size:85%;line-height:120%;vertical-align:top">0</sup>/β<sup style="font-size:85%;line-height:120%;vertical-align:top">0</sup> genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte-matched related HSC donor is not available. Since receiving conditional marketing authorization for ZYNTEGLO, the Company has continued to advance its commercialization readiness activities. T<span style="color:#000000;">hrough September 30, 2019, the Company had not generated any revenue from product sales and had not capitalized any inventory costs related to the production of ZYNTEGLO.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2019, the Company had cash, cash equivalents and marketable securities of $1.41 billion. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its existing cash, cash equivalents and marketable securities will be sufficient to fund current planned operations for at least the next twelve months.  </p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1992-04-16
CY2019Q3 us-gaap Investments And Cash
InvestmentsAndCash
1410000000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the <span style="color:#000000;">reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially</span> from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes.</p>
CY2019Q3 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
20017000
CY2019Q3 blue Equity Securities Unrealized Loss
EquitySecuritiesUnrealizedLoss
7628000
CY2019Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
12389000
CY2019Q3 blue Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
1110040000
CY2019Q3 blue Marketable Securities Unrealized Gains
MarketableSecuritiesUnrealizedGains
3317000
CY2019Q3 blue Marketable Securities Unrealized Loss
MarketableSecuritiesUnrealizedLoss
7896000
CY2019Q3 us-gaap Marketable Securities
MarketableSecurities
1105461000
CY2018Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
20017000
CY2018Q4 blue Equity Securities Unrealized Gain
EquitySecuritiesUnrealizedGain
2150000
CY2018Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
22167000
CY2018Q4 blue Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
1488746000
CY2018Q4 blue Marketable Securities Unrealized Gains
MarketableSecuritiesUnrealizedGains
3113000
CY2018Q4 blue Marketable Securities Unrealized Loss
MarketableSecuritiesUnrealizedLoss
3011000
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
1488848000
us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
90 days or less
CY2019Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2018Q4 blue Accrued Collaboration Research Costs Current
AccruedCollaborationResearchCostsCurrent
3358000
CY2019Q3 blue Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
3840000
CY2018Q4 blue Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
5451000
CY2019Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2018Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2019Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
93200000
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
787500000
CY2019Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
157500000
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
315300000
CY2019Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
100000
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
900000
CY2019Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
100000
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
2100000
CY2019Q3 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2018Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2019Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
12400000
CY2018Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
22200000
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
176673000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
275798000
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32576000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29176000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
144097000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
246622000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
33867000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
28567000
CY2019Q3 blue Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
18785000
CY2018Q4 blue Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
21618000
CY2019Q3 blue Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
15983000
CY2018Q4 blue Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
11891000
CY2019Q3 blue Accrued Collaboration Research Costs Current
AccruedCollaborationResearchCostsCurrent
16590000
CY2019Q3 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
3014000
CY2018Q4 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
7739000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1921000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1830000
CY2018Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1424000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18479000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
17515000
CY2019Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
112479000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
99393000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
127300000
CY2019Q3 us-gaap Lease Cost
LeaseCost
8843000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
125800000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
8843000
us-gaap Operating Lease Cost
OperatingLeaseCost
26244000
us-gaap Lease Cost
LeaseCost
26244000
us-gaap Operating Lease Payments
OperatingLeasePayments
22484000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y7M6D
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0622
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7751000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
33909000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
35816000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
31052000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
31540000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
119888000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
259956000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
63999000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
195957000
blue Increase In Purchase Commitment Remaining Minimum Amount Committed
IncreaseInPurchaseCommitmentRemainingMinimumAmountCommitted
33600000
blue Deferred Revenue Released
DeferredRevenueReleased
24600000
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
300000
CY2018Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
185.00
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48700000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
2200000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
2000000.0
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2100000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
126000000.0
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29800000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
80800000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38546000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29797000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
125998000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
80849000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38546000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29797000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
125998000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
80849000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4643000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
108.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1447000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
134.41
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
333000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
50.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
288000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
133.36
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5469000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
117.63
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2680000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
92.49
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5469000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
117.63
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
300000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
16800000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6616000
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6616000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5483000
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5483000

Files In Submission

Name View Source Status
0001564590-19-039179-index-headers.html Edgar Link pending
0001564590-19-039179-index.html Edgar Link pending
0001564590-19-039179.txt Edgar Link pending
0001564590-19-039179-xbrl.zip Edgar Link pending
blue-10q_20190930.htm Edgar Link pending
blue-10q_20190930_htm.xml Edgar Link completed
blue-20190930.xsd Edgar Link pending
blue-20190930_cal.xml Edgar Link unprocessable
blue-20190930_def.xml Edgar Link unprocessable
blue-20190930_lab.xml Edgar Link unprocessable
blue-20190930_pre.xml Edgar Link unprocessable
blue-ex311_7.htm Edgar Link pending
blue-ex312_9.htm Edgar Link pending
blue-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending